News

Sustainability in lateral flow testing is broader than material substitution. This article explores how material design, reagent strategy, manufacturing yield, performance testing, supply chain choices and at-source testing can reduce waste across the full lateral flow test lifecycle.

Fleet Bioprocessing is attending Med-Tech Expo 2026 at the NEC Birmingham on Wednesday 3rd June. We look forward to meeting researchers and industry partners working in diagnostics, assay technologies and healthcare innovation.

This article compares sandwich vs competitive assays in ELISA and lateral flow, focusing on format selection, reagent strategy and assay development considerations.

Fleet Bioprocessing will be attending Sensors for Health 2026 at Swansea University on 29 April. The event brings together researchers and industry working in health related sensor development, diagnostics and translation.

Fleet Bioprocessing has been re-certified for Cyber Essentials, demonstrating effective controls against common cyber attacks under the UK government-backed scheme.

Performance verification is the stage at which a lateral flow assay moves from development understanding to formal analytical evidence. This article explains how intended use and design inputs shape verification strategy, how CLSI-guided studies are structured, and why robust documentation is critical for transfer, submission, and product readiness.